Abstract Number: 2114 • ACR Convergence 2023
The Relationship Between Disease Activity of Rheumatoid Arthritis and Kidney Function
Background/Purpose: Chronic kidney disease (CKD) is a common comorbidity of rheumatoid arthritis (RA) affecting 10-20% of patients. However, the influence of the longitudinal RA disease…Abstract Number: 0857 • ACR Convergence 2023
Change in Albuminuria in Patients with ANCA-Associated Vasculitis Treated with Avacopan
Background/Purpose: Urinary albumin:creatinine ratio (UACR) is an important biomarker of active glomerulonephritis, a common complication of antineutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV). In most glomerular…Abstract Number: 2289 • ACR Convergence 2023
Short and Long Term Outcomes of Patients with Pure Membranous Lupus Nephritis Compared to Patients with Proliferative Disease
b>Background/Purpose: Patients with pure membranous lupus nephritis (LN) are known to have a different disease course than those with proliferative disease. The aim of this…Abstract Number: 0930 • ACR Convergence 2023
Genetic Risk Profiles of Patients with Lupus Nephritis to Identify Those at Risk for Kidney Deterioration and Eventual Damage
Background/Purpose: Many genetic variants are associated with lupus nephritis (LN). Yet, the majority of associated variants have a small effect size; hence, they convey small…Abstract Number: 2336 • ACR Convergence 2023
Identification of Urine Metabolites Linked to Disease Activity That Are Modulated by Anifrolumab in a Phase 2 LN Trial Using Untargeted Metabolomics Analysis
Background/Purpose: LN is a severe complication of SLE, affecting 21%–48% of patients.1 Development of noninvasive diagnostic tests for LN is ongoing; urinary biomarkers have good…Abstract Number: 1112 • ACR Convergence 2023
AR882, a Potent Uricosuric Agent, Shows Favorable Uric Acid Excretion Profile Following Multiple Doses
Background/Purpose: The uric acid transporter inhibitor (URAT1) is responsible for the reabsorption of filtered uric acid from the renal tubular lumen. Uricosuric agents inhibit URAT1…Abstract Number: 2378 • ACR Convergence 2023
Longitudinal Trajectories of Renal Function in ANCA-Associated Vasculitis: Findings from the Expanded Mass General Brigham Cohort
Background/Purpose: ANCA-associated vasculitis (AAV) commonly causes renal damage, leading to a spectrum of chronic kidney disease (CKD) and end-stage renal disease (ESRD). Quantitative descriptions of…Abstract Number: 1116 • ACR Convergence 2023
The Current State of Sodium-Glucose Cotransporter Type 2 Inhibitor Use Among Patients with Gout at a Tertiary Academic Healthcare System
Background/Purpose: A substantial proportion of gout patients have type 2 diabetes (T2DM), heart failure (HF), and chronic kidney disease (CKD), for which SGLT2i treatment is…Abstract Number: 2379 • ACR Convergence 2023
A Real-World Descriptive Study of Renal Outcomes Among Patients with ANCA-Associated Vasculitis Initiating Remission Induction Therapy
Background/Purpose: ANCA-associated vasculitis (AAV) is a group of rare autoimmune diseases characterized by inflammation and necrosis of small- to medium-sized blood vessels, commonly affecting the…Abstract Number: 1117 • ACR Convergence 2023
Serum Urate Change Among Gout Patients Initiating Sodium-Glucose Cotransporter Type 2 Inhibitors (SGLT2i) vs. Sulfonylureas: A Comparative Effectiveness Analysis
Background/Purpose: Sodium-glucose cotransporter type 2 inhibitors (SGLT2i) are currently indicated as second-line therapy for type 2 diabetes and are also approved for the treatment of…Abstract Number: 2380 • ACR Convergence 2023
Renal Survival Rate of ANCA-associated Vasculitis in Korea: A Nationwide Population-Based Study Using Claims Data
Background/Purpose: ANCA-associated vasculitis (AAV) is a rare systemic autoimmune disease with varying reports of incidence rates and clinical manifestations. Renal involvement is one of the…Abstract Number: 1125 • ACR Convergence 2023
A Rheumatologic Clinical Profile of the VEXAS Syndrome: Results from a Survey Conducted Among Rheumatologic Units of 126 Hospitals Across Spain
Background/Purpose: The newly described VEXAS syndrome is a very heterogenous disease with rheumatologic and hematologic manifestations, caused by somatic mutations affecting UBA1 gene, that still…Abstract Number: 2382 • ACR Convergence 2023
Relapse of Patients with ANCA-associated Vasculitis Who Are on Dialysis
Background/Purpose: It is known that disease activity of ANCA-associated vasculitis (AAV) is decreased after dialysis. However, most studies have been conducted on Caucasians, and factors…Abstract Number: 1394 • ACR Convergence 2023
Comorbidities, Not Long-Term Use of Nonsteroidal Anti-Inflammatory Drugs, May Be Associated with Chronic Kidney Disease in Patients with Ankylosing Spondylitis: A Nationwide Population-Based Study
Background/Purpose: Nonsteroidal anti-inflammatory drugs (NSAIDs) are commonly prescribed as first-line treatment for symptom relief and inflammation reduction in patients with ankylosing spondylitis (AS). However, long-term…Abstract Number: 2493 • ACR Convergence 2023
Renal Prognosis of Dialysis-dependent Patients at Baseline in ANCA-associated Vasculitis
Background/Purpose: Renal involvement in ANCA-associated vasculitides (AAV) is an organ- and life-threatening manifestation and therefore an important prognostic factor. However, the identification of predictive factors…
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 6
- Next Page »